Vbi Vaccines Stock Performance
| VBIVQ Stock | 0.0005 0.00 0.000004% |
The firm has a beta of 0.36, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, VBI Vaccines' returns are expected to increase less than the market. However, during the bear market, the loss of holding VBI Vaccines is expected to be smaller as well. At this point, VBI Vaccines has a negative expected return of -1.24%. Please make sure to validate VBI Vaccines' variance, skewness, as well as the relationship between the Skewness and market facilitation index , to decide if VBI Vaccines performance from the past will be repeated at future time.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days VBI Vaccines has generated negative risk-adjusted returns adding no value to investors with long positions. Even with uncertain performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in January 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors. ...more
1 | VBI Vaccines Issues Voluntary Nationwide Recall of all PreHevbrio Vaccine Due to Discontinuation of Company Operations | 11/15/2024 |
2 | VBI Vaccines Provides an Update on its Restructuring Proceedings and Announces Partial Revocation Order from the British Columbia Securities Commission | 12/10/2024 |
| Begin Period Cash Flow | 62.6 M |
VBI |
VBI Vaccines Relative Risk vs. Return Landscape
If you would invest 2.00 in VBI Vaccines on September 27, 2024 and sell it today you would lose (1.95) from holding VBI Vaccines or give up 97.5% of portfolio value over 90 days. VBI Vaccines is currently producing negative expected returns and takes up 29.8543% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than VBI, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
VBI Vaccines Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for VBI Vaccines' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as VBI Vaccines, and traders can use it to determine the average amount a VBI Vaccines' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0415
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | VBIVQ |
Estimated Market Risk
| 29.85 actual daily | 96 96% of assets are less volatile |
Expected Return
| -1.24 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average VBI Vaccines is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of VBI Vaccines by adding VBI Vaccines to a well-diversified portfolio.
VBI Vaccines Fundamentals Growth
VBI Stock prices reflect investors' perceptions of the future prospects and financial health of VBI Vaccines, and VBI Vaccines fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on VBI Stock performance.
| Revenue | 8.68 M | ||||
| Net Income | (92.84 M) | ||||
| Total Debt | 50.77 M | ||||
| Cash Flow From Operations | (60.88 M) | ||||
| Total Asset | 86.95 M | ||||
| Retained Earnings | (582.45 M) | ||||
About VBI Vaccines Performance
Assessing VBI Vaccines' fundamental ratios provides investors with valuable insights into VBI Vaccines' financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the VBI Vaccines is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
VBI Vaccines is entity of United States. It is traded as Stock on NASDAQ exchange.Things to note about VBI Vaccines performance evaluation
Checking the ongoing alerts about VBI Vaccines for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for VBI Vaccines help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| VBI Vaccines generated a negative expected return over the last 90 days | |
| VBI Vaccines has high historical volatility and very poor performance | |
| VBI Vaccines has some characteristics of a very speculative penny stock | |
| VBI Vaccines has a very high chance of going through financial distress in the upcoming years | |
| The company reported the revenue of 8.68 M. Net Loss for the year was (92.84 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| VBI Vaccines generates negative cash flow from operations | |
| VBI Vaccines has a frail financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: VBI Vaccines Provides an Update on its Restructuring Proceedings and Announces Partial Revocation Order from the British Columbia Securities Commission |
- Analyzing VBI Vaccines' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether VBI Vaccines' stock is overvalued or undervalued compared to its peers.
- Examining VBI Vaccines' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating VBI Vaccines' management team can have a significant impact on its success or failure. Reviewing the track record and experience of VBI Vaccines' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of VBI Vaccines' stock. These opinions can provide insight into VBI Vaccines' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for VBI Stock Analysis
When running VBI Vaccines' price analysis, check to measure VBI Vaccines' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VBI Vaccines is operating at the current time. Most of VBI Vaccines' value examination focuses on studying past and present price action to predict the probability of VBI Vaccines' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VBI Vaccines' price. Additionally, you may evaluate how the addition of VBI Vaccines to your portfolios can decrease your overall portfolio volatility.